$GLSI
Greenwich LifeSciences, Inc.

2023 Q4 Form 10-Q Financial Statement

#000149315223037702 Filed on October 19, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $503.1K $340.0K $659.6K
YoY Change 15.23% -48.45% 214.7%
% of Gross Profit
Research & Development $2.333M $2.158M $1.723M
YoY Change -5.09% 25.22% 162.29%
% of Gross Profit
Depreciation & Amortization $3.610K $0.00 $900.00
YoY Change 301.11% -100.0% 0.0%
% of Gross Profit
Operating Expenses $2.836M $2.503M $2.383M
YoY Change -2.03% 5.03% 174.96%
Operating Profit -$2.503M -$2.383M
YoY Change 5.03% 174.96%
Interest Expense $89.29K $110.0K $64.04K
YoY Change -14.28% 71.77% 1693.84%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.747M -$2.390M -$2.319M
YoY Change -1.57% 3.06% 168.68%
Income Tax
% Of Pretax Income
Net Earnings -$2.747M -$2.392M -$2.319M
YoY Change -1.57% 3.14% 168.68%
Net Earnings / Revenue
Basic Earnings Per Share -$0.19 -$0.18
Diluted Earnings Per Share -$0.21 -$0.19 -$180.8K
COMMON SHARES
Basic Shares Outstanding 12.85M shares 12.85M shares 12.82M shares
Diluted Shares Outstanding 12.85M shares 12.82M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.989M $9.140M $15.64M
YoY Change -48.1% -41.55% -45.9%
Cash & Equivalents $6.989M $9.144M $15.64M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $6.989M $9.140M $15.64M
YoY Change -48.1% -41.55% -45.9%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $5.395K $9.913K $9.903K
YoY Change -40.05% 0.1% -26.75%
TOTAL ASSETS
Total Short-Term Assets $6.989M $9.140M $15.64M
Total Long-Term Assets $5.395K $9.913K $9.903K
Total Assets $6.995M $9.150M $15.65M
YoY Change -48.1% -41.53% -45.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $256.3K $230.0K $220.9K
YoY Change 16.06% 4.14% -25.35%
Accrued Expenses $38.09K $70.00K $17.03K
YoY Change -9.44% 311.04% -89.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $294.4K $297.3K $237.9K
YoY Change 11.98% 24.97% -47.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $294.4K $297.3K $237.9K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $294.4K $297.3K $237.9K
YoY Change 11.98% 24.97% -47.73%
SHAREHOLDERS EQUITY
Retained Earnings -$50.36M -$47.62M -$38.68M
YoY Change 21.44% 23.1%
Common Stock $57.06M $56.47M $54.09M
YoY Change 4.35% 4.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.700M $8.853M $15.41M
YoY Change
Total Liabilities & Shareholders Equity $6.995M $9.150M $15.65M
YoY Change -48.1% -41.53% -45.89%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$2.747M -$2.392M -$2.319M
YoY Change -1.57% 3.14% 168.68%
Depreciation, Depletion And Amortization $3.610K $0.00 $900.00
YoY Change 301.11% -100.0% 0.0%
Cash From Operating Activities -$2.159M -$1.800M -$1.550M
YoY Change -0.53% 16.14% 73.23%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -2.159M -1.800M -1.550M
Cash From Investing Activities
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash -2.159M -1.800M -1.550M
YoY Change -0.53% 16.14% 73.23%
FREE CASH FLOW
Cash From Operating Activities -$2.159M -$1.800M -$1.550M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
dei Entity Central Index Key
EntityCentralIndexKey
0001799788
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39555
dei Entity Registrant Name
EntityRegistrantName
GREENWICH LIFESCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-5473709
dei Entity Address Address Line1
EntityAddressAddressLine1
3992 Bluebonnet Dr.
dei Entity Address Address Line2
EntityAddressAddressLine2
Building 14
dei Entity Address City Or Town
EntityAddressCityOrTown
Stafford
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77477
dei City Area Code
CityAreaCode
(832)
dei Local Phone Number
LocalPhoneNumber
819-3232
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
GLSI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12848165 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9143619 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13468026 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6294 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
9003 usd
CY2023Q3 us-gaap Assets
Assets
9149913 usd
CY2022Q4 us-gaap Assets
Assets
13477029 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
230902 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
220845 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
66385 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
42060 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
297287 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
262905 usd
CY2023Q3 us-gaap Liabilities
Liabilities
297287 usd
CY2022Q4 us-gaap Liabilities
Liabilities
262905 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12848165 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12848165 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12848165 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12848165 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
12848 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
12848 usd
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
56457608 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
54674042 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47617830 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41472766 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
8852626 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13214124 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9149913 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13477029 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2158167 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1723493 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5365641 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4017564 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
344758 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
659568 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1126192 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1128007 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2502925 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
2383061 usd
us-gaap Operating Expenses
OperatingExpenses
6491833 usd
us-gaap Operating Expenses
OperatingExpenses
5145571 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2502925 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2383061 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6491833 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5145571 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
111136 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
64037 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
346769 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
110846 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2391789 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2319024 usd
us-gaap Net Income Loss
NetIncomeLoss
-6145064 usd
us-gaap Net Income Loss
NetIncomeLoss
-5034725 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
CY2023Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
12848165 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12848165 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
12823447 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12823447 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
12848165 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12848165 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
13067620 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13067620 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
26831712 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
165267 usd
CY2022Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
5513711 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1969628 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
19513640 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
224503 usd
CY2022Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2022505 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-746073 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
16969565 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
759573 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
893181 shares
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2319024 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
15410114 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13214124 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
594522 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2124902 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
11683744 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
594522 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1628373 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
10649893 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
10649893 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
594522 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2391789 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
8852626 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
8852626 usd
us-gaap Net Income Loss
NetIncomeLoss
-6145064 usd
us-gaap Net Income Loss
NetIncomeLoss
-5034725 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
2709 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
2709 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1783566 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1149343 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
10057 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
24325 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-147293 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4324407 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4029966 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
7536216 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-7536216 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4324407 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11566182 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13468026 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27204269 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9143619 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15638087 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
220845 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
2555 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
220845 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
908362 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
120 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
2009657 shares
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
15181 shares
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
34157 usd
CY2023Q3 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
519828 shares
CY2022Q3 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
519828 shares
CY2023Q3 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
7536216 usd
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0 shares
CY2023Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
33338 usd
CY2023Q3 us-gaap Share Price
SharePrice
8.84
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
20174 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.1875
CY2023Q3 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2025-09-24
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
20174 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1498128 shares
CY2022Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.63
us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
9512356 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.032 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.06 pure
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3032062 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
6480294 usd

Files In Submission

Name View Source Status
0001493152-23-037702-index-headers.html Edgar Link pending
0001493152-23-037702-index.html Edgar Link pending
0001493152-23-037702.txt Edgar Link pending
0001493152-23-037702-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
glsi-20230930.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
glsi-20230930_cal.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
glsi-20230930_lab.xml Edgar Link unprocessable
glsi-20230930_pre.xml Edgar Link unprocessable
glsi-20230930_def.xml Edgar Link unprocessable